Navigation Links
Warwick joins $3.4 million Anglo-Canadian quest for new weapons in war against antibiotic resistance
Date:1/9/2012

University of Warwick researchers have teamed up with Canadian scientists on a 2.2 million project to search for new antibiotics which will beat resistance in deadly "superbugs".

The University of Warwick is part of a transatlantic team funded by the Canada/UK Partnership on Antibiotic Resistance, a collaboration between the UK's Medical Research Council (MRC) and the Canadian Institutes of Health Research (CIHR).

The four-year project will support high-quality research into alternatives to existing antibiotics whose effectiveness is being challenged by increasing resistance in bacteria such as E. coli and MRSA.

Professor Chris Dowson, who is leading the project at the University of Warwick, said: "Growing antibiotic resistance to the current generation of antibiotics is of huge concern worldwide.

"Antibiotics underpin many aspects of healthcare - from cancer treatment through to surgery but the pace of antibiotic resistance in some bacteria is speeding up.

"Coupled with that, there is a worrying lack of new antibiotic drugs coming through the pipeline from private drug companies.

"That's why public funding for projects like this is so vital.

"Governments need to take responsibility for funding early-stage drug discovery as we face an increasing vacuum of antibiotic research within the pharmaceutical industry."

The Anglo-Canadian partnership takes advantage of the strong academic and clinical research strengths that exist in both Canada and the UK.

The University of Warwick is part of a team in the UK including the universities of Birmingham, Sheffield and Newcastle, working alongside the universities of Guelph, McMaster, Laval and British Columbia in Canada, which will focus on increasing understanding of bacterial cell wall growth in a bid to find new targets for new antibiotics.

Dr David Roper of the University of Warwick, School of Life Sciences and co-director of the project in the UK said: "Researchers on both sides of the Atlantic will be working in teams together exploring and exploiting aspects of the way in which bacteria synthesise their cell walls as they grow.

"Many current antibiotics, including penicillin, target this process and we think there are many new aspects to exploit, if we understood the process better.

"Our coordinated research efforts will be to further define the biological elements of how bacteria build their cell walls and discover new chemicals that interfere with that process.

"Research teams in Canada and the UK have unique facilities and expertise to do this and for the first time funding from MRC and CIHR is being used to combine those assets."

Research at the University of Warwick benefits from equipment provided through funding from Advantage West Midlands' Birmingham Science City, which will also contribute to this programme.


'/>"/>

Contact: Anna Blackaby
a.blackaby@warwick.ac.uk
44-247-657-5910
University of Warwick
Source:Eurekalert

Related medicine news :

1. Warwick scientists discover how daughter cells receive the same number of chromosomes
2. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
3. AMA Joins First Lady in Fight Against Childhood Obesity
4. The West Clinic Joins Cancer Clinics of Excellence (CCE)
5. Orthopaedic Physician Dr. Brett Smith Joins Baptist Health Care as Total Joint Specialist
6. Longtime Quality Assurance Executive Randy Johnson Joins White Pine Systems as Vice President of Product Services
7. Peter Harker Joins Prometheus Research as Vice President of Sales
8. Tom Brunelle Joins StatCom as Enterprise VP, Northeast Region
9. Christina Hurnyak, Veteran Personal Injury Attorney, Joins Rudberg Law Offices, LLC
10. Don Blumenthal Joins White Pine Systems as Chief Compliance Officer
11. CURE Magazine Joins US Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... 05, 2016 , ... Francisco Canales, MD and Heather Furnas, ... Valley office. The technique utilizes the body’s own healing abilities to quickly rejuvenate ... are part of only a select few cosmetic surgeons bringing this procedure to ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active ... Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division ... completed his first three-year term as chief and began a second three-year term in ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... PROSHRED franchises from across the country gathered at the La Valencia Hotel in ... performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking away ...
(Date:2/5/2016)... ... 05, 2016 , ... Give To Cure today announced that it ... to Give To Cure’s campaign that is crowdfunding clinical trials to help find cures ... payments through a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... and CEO, will be presenting at Source Capital Group,s 2016 ... NY at 2:15 p.m. ET on Wednesday, February ... Panel discussion taking place at 3:15 p.m. ET. ... one hour after the conclusion of the live event. The ...
(Date:2/5/2016)... , February 5, 2016 ... Market Research report states that the global active pharmaceuticals ... and is predicted to reach US$185.9 bn by 2020. ... 6.50% from 2014 to 2020. The title of the ... Captive/Contract Manufactured, by Geography, and by Therapeutic Area) - ...
(Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, Inc. ... the previously announced underwritten secondary offering of 11,027,558 shares ... consisting of affiliates of Blackstone and Goldman Sachs.  The ... initial price of $96.45 per share. The selling stockholders ...  Neither Zimmer Biomet nor any of its directors, officers ...
Breaking Medicine Technology: